Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

European journal of clinical pharmacology - 1 Jan 1995

Nielsen F, Rosholm J U, Brøsen K

Abstract excerpt

Quinidine is a very potent inhibitor of CYP2D6, but the role of the enzyme in the biotransformation of quinidine has only been investigated in a single in vitro study and in two small in vivo experiments, with contradictory results. The present investigation was designed to present definite evaluation of whether quinidine is metabolised by CYP2D6. Eight poor metabolizers (PM) and 8 extensive metabolizers (EM) of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Half-Life

Share to Mixed Function Oxygenases

Share to Oxidation-Reduction

Share to Phenotype

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 8582470
DOI: 10.1007/BF00194341

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.PMID 8582470Read ↗

Lack of relationship between debrisoquine oxidation phenotype and the pharmacokinetics of quinine.Semantic proximity Read ↗

The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.Semantic proximity Read ↗

Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Semantic proximity Read ↗

Clinical consequences of polymorphic drug oxidation.Semantic proximity Read ↗

Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms.Semantic proximity Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine.Semantic proximity Read ↗

Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.Semantic proximity Read ↗

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.